Indirect production of no carrier added (NCA) 177Lu from irradiation of enriched 176Yb: Options for ytterbium/lutetium separation

Current Radiopharmaceuticals

Volumn 8, Issue 2, 2015, Pages 107-118

  Dash, Ashutosh ^a   Chakravarty, Rubel ^a   Pillai, Ambikalmajan M R ^c  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Russ)   (United States)

^c Molecular Group of Companies   (India)

Author keywords

Electro amalgamation; Extraction chromatography (EXC); Neutron irradiation; No carrier added (NCA)177Lu; Peptide receptor radionuclide therapy (PRRT); Separation

Indexed keywords

LUTETIUM 177; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTERBIUM 176; ISOTOPE; LUTETIUM; YTTERBIUM;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; DOSIMETRY; DRUG ACTIVITY; DRUG ANALYSIS; DRUG PURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE; ION EXCHANGE CHROMATOGRAPHY; LARGE SCALE PRODUCTION; NEUTRON RADIATION; NO CARRIER ADDED; PRIORITY JOURNAL; QUALITY CONTROL; RADIOACTIVE WASTE; RADIOCHEMISTRY; RADIOLOGICAL PARAMETERS; REDUCTION; SEPARATION TECHNIQUE; CHEMISTRY; NEUTRON;

ISOTOPES; LUTETIUM; NEUTRONS; RADIOISOTOPES; YTTERBIUM;

EID: 84940901368     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150312161942     Document Type: Article

References (65)

1. [1] Das, T.; Pillai, M.R.A. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl. Med. Biol. 2013, 40(1), 23-32.
2. [2] Cutler, C.S.; Hennkens, H.M.; Sisay, N.; Huclier-Markai, S.; Jurisson, S.S. Radiometals for combined imaging and therapy. Chem. Rev., 2013, 113(2), 858-883.
3. [3] Dash, A.; Knapp, FF. Jr.; Pillai, M.R.A. Targeted Radionuclide Therapy -An Overview. Curr. Radiopharm., 2013, 6(3), 152-180.
4. [4] Ramogida, C.F.; Orvig, C. Tumour targeting with radiometals for diagnosis and therapy. Chem. Commun. (Camb), 2013, 49(42), 4720-4739.
5. [5] Pillai, M.R.A. Metallic Radionuclides and Therapeutic Radiopharmaceuticals, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195, Warsaw, Poland, 2010, ISBN: 8392901371, 9788392901372.
6. [6] Chakraborty, S.; Vimalnath, K.V.; Lohar, S.P.; Shetty, P.; Dash, A. On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: The Indian experience. J. Radioanal. Nucl. Chem., 2014, 302, 233-243.
7. [7] Knapp, F.F. Jr.; Mirzadeh, S.; Beets, A.L.; Du, M. Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for applications in nuclear medicine, oncology and interventional cardiology. J. Radioanal. Nucl. Chem., 2005, 263(2), 503-509.
8. [8] Firestone, R. Table of Isotopes. 8th ed. New York: Wiley, 1996.
9. [9] Kam, B.L.; Teunissen, J.J.; Krenning, E.P.; de Herder, W.W.; Khan, S.; van Vliet, EI.; Kwekkeboom, D.J. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(Suppl 1), 103-112.
10. [10] Bodei, L.; Cremonesi, M.; Grana, C.M.; Fazio, N.; Iodice, S.; Baio, S.M.; Bartolomei, M.; Lombardo D.; Ferrari, M.E.; Sansovini, M.; Chinol, M.; Paganelli, G. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(12), 2125-2135.
11. [11] Swärd, C.; Bernhardt, P.; Johanson, V.; Schmitt, A.; Ahlman, H.; Stridsberg, M.; Forssell-Aronsson, E.; Nilsson, O.; Kölby, L. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer. Biother. Radiopharm., 2008, 23(1), 114-120.
12. [12] Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26(13), 2124-2130.
13. [13] Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. Mol. Imaging, 2001, 28(7), 836-846.
14. [14] Kwekkeboom, D.J.; Bakker, W.H.; Kooij, P.P.; Konijnenberg, M.W.; Srinivasan, A.; Erion, J.L.; Schmidt, M.A.; Bugaj, J.L.; de Jong, M.; Krenning, E.P. [177Lu-DOTAOT-tyr3]octreotate: comparison with [111In-DTPA]octreotide in patients. Eur. J. Nucl. Med. Mol. Imaging, 2001, 28(9), 1319-1325.
15. [15] Esser, J.P.; Krenning, E.P.; Teunissen, J.J.; Kooij, P.P.; van Gameren, A.L.; Bakker, W. H.; Kwekkeboom, D.J. Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging., 2006, 33(11), 1346-1351.
16. [16] Forrer, F.; Uusijärvi, H.; Storch, D.; Maecke, H.R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J. Nucl. Med., 2005, 46(8), 1310-1316.
17. [17] Gupta, S.K.; Singla, S.; Bal, C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer. Biother. Radiopharm., 2012, 27(9), 593-599.
18. [18] Kwekkeboom, D.J.; Teunissen, J.J.; Bakker, W.H.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; Esser, J.P.; Kam, B.L.; Krenning, E. P. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol., 2005, 23(12), 2754-2762.
19. [19] Bakker, W.H.; Breeman, W.A.; Kwekkeboom, D.J.; De Jong, L.C.; Krenning, E.P. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. Q.J. Nucl. Med. Mol. Imaging, 2006, 50(4), 265-271.
20. [20] Forrer, F.; Uusijärvi, H.; Storch, D.; Maecke, H.R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J. Nucl. Med. 2005, 46(8), 1310-1316.
21. [21] Garkavij, M.; Nickel, M.; Sjögreen-Gleisner, K.; Ljungberg, M.; Ohlsson, T.; Wingårdh, K.; Strand, S.E.; Tennvall, J. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer, 2010, 116(4 Suppl), 1084-1092.
22. [22] Wehrmann, C.; Senftleben, S.; Zachert, C.; Müller, D.; Baum, R. P. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer. Biother. Radiopharm., 2007, 22(3), 406-416.
23. [23] Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26(13), 2124-2130.
24. [24] Garkavij, M.; Nickel, M.; Sjögreen-Gleisner, K.; Ljungberg, M.; Ohlsson, T.; Wingårdh, K.; Strand S. E.; Tennvall, J. 177Lu-[DOTA0,Tyr3]octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer, 2010, 116(4 Suppl):1084-1092.
25. [25] Khan, S.; Krenning, E.P.; van Essen, M.; Kam, B.L.; Teunissen, J.J.; Kwekkeboom, D.J. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J. Nucl Med., 2011, 52(9), 1361-1368.
26. [26] Ezziddin, S.; Attassi, M.; Yong-Hing, C.J.; Ahmadzadehfar, H.; Willinek, W.; Grünwald, F.; Guhlke, S.; Biersack, H.J.; Sabet, A. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med., 2014, 55(2), 183-190.
27. [27] Sabet, A.; Ezziddin, K.; Pape, U.F.; Ahmadzadehfar, H.; Mayer, K.; Pöppel, T.; Guhlke, S.; Biersack, H.J.; Ezziddin, S. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl Med., 2013, 54(11), 1857-1861.
28. [28] Ezziddin, S.; Sabet, A.; Heinemann, F.; Yong-Hing, C. J.; Ahmadzadehfar, H.; Guhlke, S.; Höller, T.; Willinek, W.; Boy, C.; Biersack, H. J. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J. Nucl. Med., 2011, 52(8), 1197-1203.
29. [29] Swärd, C.; Bernhardt, P.; Ahlman, H.; Wängberg, B.; Forssell-Aronsson, E.; Larsson, M.; Svensson, J.; Rossi-Norrlund, R.; Kölby, L. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J. Surg., 2010, 34(6), 1368-1372.
30. [30] van Essen, M.; Krenning, E.P.; Kam, B.L.; de Herder, W.W.; Feelders, R.A.; Kwekkeboom, D.J. Salvage therapy with (177)Luoctreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med., 2010, 51(3), 383-389.
31. [31] Breeman, W.A.; Mearadji, A.; Capello, A.; Bernard, B.F.; van Eijck, C.H.; Krenning, E. P.; de Jong, M. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. Int. J. Cancer, 2003, 104(3), 376-379.
32. [32] Mikolajczak, R.; Parus, J.L.; Pawlak, D.; Zakrzewska, E.; Michalak, W.; Sasinowska, I. Reactor produced 177Lu of specific activity and purity suitable for medical applications. J. Radioanal. Nucl. Chem., 2003, 257, 53-57
33. [33] Mirzadeh, S.; Du, M.; Beets, A.L.; Knapp F.F. Jr. Method for preparing high specific activity 177Lu. United States Patent 6716353 (2004).
34. [34] Le, V.S. Specific Radioactivity of Neutron Induced Radioisotopes: Assessment methods and application for medically useful 177Lu production as a case. Molecules, 2011, 16(1), 818-846.
35. [35] Zhernosekov, K.P.; Perego, R.C.; Dvorakova, Z.; Henkelmann, R.; Tuerler, A. Target burn-up corrected specific activity of 177Lu produced via 176Lu(n,')177Lu nuclear reactions. Appl. Radiat. Isot., 2008, 66, 1218-1220.
36. [36] Nirel, Y. Production of 177Lu by neutron activiation of 176Lu. J. Radioanal. Nucl. Chem., 2004, 262, 563-567.
37. [37] Knapp F.F. Jr. Lutetium-177 -Broad production capabilities are expected to stimulate clinical applications of this important therapeutic radioisotope, Report on the Technical Meeting on Therapeutic Radiopharmaceuticals. IAEA, Vienna (Austria); 16-20 Nov 2009, Available at: http://www.iaea.org/inis/collection/NCLCollectionStore/Public/43/005/43005457.pdf. [Accessed April 20, 2014].
38. [38] Balasubramanian, P.S. Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target. J. Radioanal. Nucl. Chem., 1994, 185, 305-310.
39. [39] Knapp, F.F. Jr.; Ambrose, K.R.; Beets, A.L.; Luo, H.; McPherson, D. W.; Mirzadeh, S. Nuclear medicine program progress report for quarter ending September 30, 1995. ORNL/TM-13107.
40. [40] Morcos, N.; Zaw, M.; Pellegrini, P.; Greguric, I.; Nevissi, A.; Morcos, N. Alternative chromatographic processes for no-carrier added 177Lu radioisotope separation Part II. The conventional column chromatographic separation combined with HPLC for high purity. J. Radioanal. Nucl. Chem., 2008, 277(3), 675-683.
41. [41] Horwitz, E.P.; Mc Alister, D.R.; Bond, A.H.; Barrans, R.E.; Williamson, J. M. A process for the separation of 177Lu from neutron irradiated 176Yb targets. Appl. Radiat. Isot., 2005, 63, 23-36.
42. [42] Hashimoto, K.; Matsuoka, H.; Uchida, S. Production of no-carrieradded 177Lu via the 176Yb(n, ')177Yb _177Lu process. J. Radioanal. Nucl. Chem., 2003, 255(3), 575-579.
43. [43] Lebedev, N.A.; Novgorodov, A.F.; Misiak, R.; Brockmann, J.; Roesch, F. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,')177Yb_177Lu process. Appl. Radiat. Isot., 2000, 53, 421-425.
44. [44] Lahiri, S.; Nayak, D.; Nandy, M.; Das, N.R. Separation of carrier free lutetium produced in proton activated ytterbium with HDEHP. Appl. Radiat. Isot., 1998, 49(8), 911-913.
45. [45] Kumric, K.; Trtic-Petrovic, T.; Koumarianou, E.; Archimandritis, S.; Comor, J.J.; Supported liquid membrane extraction of 177Lu(III) with DEHPA and its application for purification of 177Lu-DOTAlanreotide, Sep. Pur. Tech., 2006, 51(3), 310-331.
46. [46] Bilewicz, A.; Zuchowska, K.; Bartos, B. Separation of Yb as YbSO4 from 176Yb target for production of 177Lu via the 176Yb(n, y)177Yb-177Lu process. J. Radioanal. Nucl. Chem., 2009, 280(1), 167-169.
47. [47] Chakravarty, R.; Das, T.; Dash, A.; Venkatesh, M. An electroamalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated 177Yb for biomedical applications. Nucl. Med. Biol., 2010, 37(7), 811-820.
48. [48] Hammond, C.R. The Elements, in Handbook of Chemistry and Physics. 2000, 81st edition. CRC press Boca Raton, FL, London, UK.
49. [49] Stary, J. Separation of transplutonium elements. Talanta., 1966, 13, 421-437.
50. [50] Denzler, F.O.; Lebedev, N.A.; Novgorodov, A.F.; Roesch, F.; Qaim, S.M. Production and radiochemical separation of 147Gd. Appl. Radiat. Isot., 1997, 48, 319-326.
51. [51] Marhol, M. Ion Exchangers in Analytical Chemistry: Their Properties and Use in Inorganic Chemistry. Academia, Praha, Prague, Czech Republic. 1982.
52. [52] Le, V.S.; Morcos, N.; Zaw, M.; Pellegrini, P.; Greguric, I. Alternative chromatographic processes for no-carrier added 177Lu radioisotope separation. Part I. Multi-column chromatographic process for clinically applicable. J. Radioanal. Nucl. Chem., 2008, 277, 663-673.
53. [53] Le, V.S.; Morcos, N.; Zaw, M.; Pellegrini, P.; Greguric, I.; Nevissi, A. Alternative chromatographic processes for no-carrier added 177Lu radioisotope separation. Part II. The conventional column chromatographic separation combined with HPLC for high purity. J. Radioanal. Nucl. Chem., 2008, 277, 675-683
54. [54] Marsh J.K. Rare earth metal amalgams, Part 1. J. Chem. Soc., 1942, 1, 398-401.
55. [55] Marsh J.K. Rare earth metal amalgams, Part 2. J. Chem. Soc., 1942, 1, 523-526.
56. [56] Marsh J.K. Rare earth metal amalgams, Part 3. J. Chem. Soc., 1943, 2, 8-10.
57. [57] Marsh J.K. Rare earth metal amalgams, Part 4. J. Chem. Soc., 1943, 2, 531-535.
58. [58] McCoy H.N. Europium and ytterbium amalgams. J. Chem. Soc., 1941, 63, 1622-1624.
59. [59] Onstott, E.I. The separation of europium from samarium by electrolysis. J. Chem. Soc., 1955, 77, 2129-2132.
60. [60] Onstott, E.I. Separation of the Lanthanons at Amalgam Cathodes. II. The separation of samarium from gadolinium and purification of europium at a lithium amalgam cathode. J. Am. Chem. Soc., 1956, 78, 2070-2076.
61. [61] Khomutov, N.E. Table of molal standard electrode potentials and their temperature coefficients in aqueous solutions at 25 °C. In: Khomutov NE, editor. Electrochemistry: Electrodeposition of metals and alloys. Achievements in Science: Chemistry Series. Moskow: Referativnyi Zhurnal Khimiya, Baltiiskaya ul.; 1969, 2-27.
62. [62] Jelinek, L.; Wei, Y.; Arai, T.; Kumagai, M. Selective Eu(III) electro-reduction and subsequent separation of Eu(II) from rare earths(III) via HDEHP impregnated resin. Solvent. Extr. Ion. Exc., 2007, 25(4), 503-513.
63. [63] Available online at: http://www.perkinelmer.com/catalog/product/id/nez347c000mc [Accessed April 20, 2014].
64. [64] Barkhaus, C. Production of non carrier added (n.c.a.) 177Lu for radiopharmaceutical applications. Ph.D. thesis. Technische Universitat Munchen. Available online at: http://mediatum.ub.tum.de/doc/1080831/1080831.pdf, 2011.
65. [65] Marhol, M. Ion Exchangers in Analytical Chemistry: Their Properties and Use in Inorganic Chemistry. Academia, Prague, 1982.